Proud D, Naclerio R M, Meyers D A, Kagey-Sobotka A, Lichtenstein L M, Valentine M D
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md.
Int Arch Allergy Appl Immunol. 1990;93(2-3):165-70. doi: 10.1159/000235296.
We performed a double-blind, placebo-controlled, crossover study using 12 subjects to determine the effects of a single 50-mg dose of captopril on the response to nasal challenge with increasing doses of allergen. Levels of kinins, histamine and N-alpha-p-tosyl-L-arginine methyl ester (TAME)-esterase activity were measured in nasal lavages, and symptom scores and the number of sneezes were recorded. Captopril had no significant effects on histamine, TAME-esterase, sneezing or symptom scores. Peak postchallenge kinin levels, however, were significantly elevated (p less than 0.05) compared to placebo, while an increase in the magnitude of the dose-response curve was of marginal significance (p = 0.058). Thus, captopril causes increases in the kinin levels in nasal secretions during the allergic response. If increased kinin levels persist or worsen with chronic therapy, it is possible that they could exacerbate allergic symptoms during repeated seasonal exposure.
我们采用12名受试者进行了一项双盲、安慰剂对照的交叉研究,以确定单次50毫克剂量的卡托普利对递增剂量变应原鼻腔激发反应的影响。在鼻腔灌洗液中测量激肽、组胺和N-α-对甲苯磺酰-L-精氨酸甲酯(TAME)酯酶活性水平,并记录症状评分和喷嚏次数。卡托普利对组胺、TAME酯酶、喷嚏或症状评分无显著影响。然而,与安慰剂相比,激发后激肽峰值水平显著升高(p<0.05),而剂量反应曲线幅度的增加具有边际显著性(p = 0.058)。因此,卡托普利会导致过敏反应期间鼻腔分泌物中激肽水平升高。如果慢性治疗期间激肽水平持续升高或恶化,则在反复季节性暴露期间它们可能会加重过敏症状。